Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Oncternal Therapeutics Inc reports Q1 loss but advances promising therapies

Oncternal Therapeutics Inc's Q1 2024 performance reflects ongoing investment in innovative therapies amidst a net loss of $8.4 million.
The company's financial stability, upcoming milestones, and engagement with analysts position it well for future growth and development.
Challenges in managing expenses, meeting clinical data timelines, and ensuring therapeutic success underscore the need for strategic decision-making and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Didi Global

Ginkgo Bioworks Holdings

Here are three penny stocks to add to your watchlist right now The post Hot Penny Stocks to Watch as May Ends  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch as May Ends

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, that will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. In the CIRLL study, zilovertamab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). The clinical trial is being conducted in collaboration with the University of California San Diego (UC San Diego) and has been partially funded by the California Institute for Regenerative Medicine (CIRM).

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022

Oncternal Therapeutics, Inc (NASDAQ:ONCT ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants James Breitmeyer – President & Chief Executive Officer Richard Vincent – Chief Financial Officer Salim Yazji – Chief Medical Officer Conference Call Participants Hartaj Singh – Oppenheimer Carl Byrnes – Northland Capital Markets Brian Petitt – BTIG Investment Banking Shubhendu Sen Roy – Brookline Capital Markets Operator Greetings and welcome to Oncternal Therapeutics, Inc Third Quarter 2022 Financial Results Call. At this time, all participants are in a listen-only mode.

Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q1 2022 Results - Earnings Call Transcript

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported financial results for the first quarter of 2022.

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2022 financial results after the U.S. financial markets close on Thursday, May 5, 2022. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company's financial results.

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results

SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has deprioritized further development of ONCT-216 to reallocate resources to zilovertamab, the Company's investigational anti-ROR1 monoclonal antibody, and its Phase 3 registrational trial that the Company expects to initiate in Q3 2022. As such, the Company has discontinued enrollment in the Phase 1/2 study evaluating ONCT-216 in patients with relapsed or refractory Ewing sarcoma.

Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma

Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q4 2021 Results - Earnings Call Transcript

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 36% and 72.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Oncternal Therapeutics (ONCT) Reports Q4 Loss, Lags Revenue Estimates

SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2021 financial results.

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2021 financial results after the U.S. financial markets close on Thursday, March 10, 2022. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company's financial results.

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results

Eyenovia

loanDepot

MannKind

Performant Financial

P3 Health Partners Inc

Pixelworks

Vaccinex Inc

Penny stocks to buy now according to insiders. The post 8 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 Penny Stocks To Buy Now According To Insiders In 2022

Insiders are scooping up shares of these penny stocks in 2022. The post 5 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy Now According To Insiders In 2022

The unemployment rate in the Eurozone dropped to a record low of 7% in December from a revised 7.1% level in the previous month, helping the STOXX Europe 600 Index record gains this morning. Investors, meanwhile, focused on some notable insider trades.

Vaccinex And 4 Other Penny Stocks Bought By Insiders

SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a key opinion leader (KOL) webinar on hematological malignancies and prostate cancer on Tuesday, January 25, 2022 from 2:30 - 4:30 pm (ET).

Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for zilovertamab, the company's investigational anti-ROR1 monoclonal antibody, the company and the FDA agreed on key elements of the company's potentially pivotal Phase 3 clinical trial of zilovertamab for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL). The FDA has also reviewed and agreed upon the key design features and operational details of the company's Phase 3 clinical trial protocol and Statistical Analysis Plan, which is being finalized based on the FDA's input.

Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma

ONCT recently presented new and impressive results at the American Society of Hematology's annual conference. I review this new data in detail below.

Oncternal Therapeutics: Trading Near Cash With Impressive Results

SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) --  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, that will be presented in a poster presentation at the American Society of Hematology (ASH) 2021 Annual Meeting. In the CIRLL study, zilovertamab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with MCL and CLL. The clinical trial is being conducted in collaboration with UC San Diego and is partially funded by the California Institute for Regenerative Medicine (CIRM).

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the Phase 2 expansion cohort of its ongoing Phase 1/2 clinical trial evaluating ONCT-216 (formerly TK216), an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma. The data update was delivered in an oral presentation at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting.

Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting

Digital Turbine

Celsius Holdings

Dow Inc

Enphase Energy

Intrepid Potash

Centrus Energy

Li Auto Inc.

Ammo

Verastem

Two new Breakout Stocks for Week 46 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfolio is up +70.5% YTD despite a record high 24 weeks out 45 weeks this year in negative conditions above the 40 MG level.

Week 46 MDA Breakout Stocks - November 2021: Short-Term Picks To Give You An Edge

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present and participate virtually at the 12th Annual Jefferies London Healthcare Conference.

Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference

Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q3 2021 Results - Earnings Call Transcript

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -18.75% and 64.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Oncternal Therapeutics (ONCT) Reports Q3 Loss, Tops Revenue Estimates

SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported financial results for the third quarter of 2021. Oncternal management will host a webcast today at 5:00 p.m. ET to provide a business update and discuss its third quarter of 2021 financial results.

Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it has joined Karolinska Institutet's NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies as a collaborative partner.

Oncternal Therapeutics Joins Karolinska Institutet's NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Cell Therapy Scientific Advisory Board (SAB). The Cell Therapy SAB is comprised of industry and academic leaders in the cell therapy field, covering important areas of expertise including cutting edge research, preclinical development, manufacturing, and clinical development.

News for Oncternal Therapeutics Inc Stock (ONCT)